English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Lupin may test Rs 2600-2700: Prakash Diwan

      Lupin may test Rs 2600-2700: Prakash Diwan

      Prakash Diwan of prakashdiwan.in is of the view that Lupin may test Rs 2600-2700.

    • Positive on Sun Pharma, Strides Arcolab: Deepak Shenoy

      Positive on Sun Pharma, Strides Arcolab: Deepak Shenoy

      Deepak Shenoy of capitalmind.in has a positive stance on Sun Pharmaceutical Industries and Strides Arcolab.

    • Like Sun Pharma, Strides Arcolab: Deepak Shenoy

      Like Sun Pharma, Strides Arcolab: Deepak Shenoy

      Deepak Shenoy, Founder of Capitalmind.in likes Sun Pharma and Strides Arcolab and feels that pharma as a space is worth looking into.

    • Wait 2-3 qtrs to buy Lupin, Sun Pharma: Prabhudas Lilladher

      Wait 2-3 qtrs to buy Lupin, Sun Pharma: Prabhudas Lilladher

      Pharma Analyst Surajit Pal is not very keen on holding pharma biggies, given the newsflows that are associated with them. Lupin first quarter earnings have been disappointing and Pal believes the pain is going to continue for two-three months. Another big-ticket stock Sun Pharma too have seen a steep fall after it issued profit warning.

    • Accumulate Sun Pharma with 18-24 months view: Devang Mehta

      Accumulate Sun Pharma with 18-24 months view: Devang Mehta

      Devang Mehta of Anand Rathi Financial Services recommends accumulating Sun Pharmaceutical Industries with a view of 18-24 months.

    • Prefer Glenmark Pharma: Anand Tandon

      Prefer Glenmark Pharma: Anand Tandon

      Anand Tandon, Market Expert is of the view that one may prefer Glenmark Pharma.

    • Buy Sun Pharmaceutical Industries: Mahantesh Sabarad

      Buy Sun Pharmaceutical Industries: Mahantesh Sabarad

      Mahantesh Sabarad, Deputy VP of Research at SBI Capital Securities recommends buying Sun Pharmaceutical Industries.

    • See downside of 5-7% in Sun Pharma: Sachin Shah

      See downside of 5-7% in Sun Pharma: Sachin Shah

      Sachin Shah of Emkay Investment Managers is of the view that one may see 5-7 percent downside in Sun Pharmaceutical Industries.

    • Prefer Strides Arcolab, Sun Pharma: Deepak Shenoy

      Prefer Strides Arcolab, Sun Pharma: Deepak Shenoy

      Deepak Shenoy of Capital Mind is of the view that one may prefer Strides Arcolab and Sun Pharma.

    • Hold Reliance Industries; target Rs 980: Gaurang Shah

      Hold Reliance Industries; target Rs 980: Gaurang Shah

      Gaurang Shah of Geojit BNP Paribas Financial Services is of the view that one may hold Reliance Industries with a target Rs 980.

    • Hold Sun Pharma: Mayuresh Joshi

      Hold Sun Pharma: Mayuresh Joshi

      Mayuresh Joshi - fund manager - PMS at Angel Broking recommends holding Sun Pharma.

    • Check out: Investment ideas by market experts

      Check out: Investment ideas by market experts

      Watch the interview of Mayuresh Joshi of Angel Broking to answer all your stock queries and Kalpesh Ashar of Full Circle Financial Planners & Advisors is answer our few personal finance queries.

    • Stay invested in Sun Pharma: Mayuresh Joshi

      Stay invested in Sun Pharma: Mayuresh Joshi

      According to Mayuresh Joshi of Angel Broking, one may stay invested in Sun Pharmaceutical Industries.

    • Expect upside in Sun Pharma: Abhishek Sharma

      Expect upside in Sun Pharma: Abhishek Sharma

      Abhishek Sharma, pharma analyst at IIFL is of the view that one may see upside in Sun Pharmaceutical Industries.

    • Positive on Lupin on strong pipeline for US mkt: IIFL

      Positive on Lupin on strong pipeline for US mkt: IIFL

      Pharma Analyst, Abhishek Sharma of IIFL spoke with Ekta Batra & Anuj Singhal of CNBC-TV18. He shared his reading and outlook on the pharmaceutical space.

    • Invest in Sun Pharma, says Mayuresh Joshi

      Invest in Sun Pharma, says Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one may invest in Sun Pharmaceutical Industries.

    • See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal

      See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal

      or the investors who are holding the stock should continue to hold it but fresh entry should be made only if it corrects from the current levels, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

    • Here are top 10 stocks to focus on March 24

      Here are top 10 stocks to focus on March 24

      Here are top 10 stocks to focus on March 24 – HDFC, Wockhardt, Geometric, GMR Infra, Sun Pharma, Ranbaxy, Hero Moto, JSPL, Adani Power and Aarti Drugs.

    • Exit Biocon, says Vishal Malkan

      Exit Biocon, says Vishal Malkan

      Vishal Malkan of malkansview.com is of the view that one may exit Biocon.

    • Pharma safe space: Sandip Sabharwal

      Pharma safe space: Sandip Sabharwal

      Sandip Sabharwal of asksandipsabharwal.com is of the view that pharma could be a safe pocket.

    • Buy Ranbaxy Labs 780 Call: VK Sharma

      Buy Ranbaxy Labs 780 Call: VK Sharma

      VK Sharma of HDFC Securities recommends buying Ranbaxy Labs 780 Call.

    • Here are top 10 stocks to focus on March 4

      Here are top 10 stocks to focus on March 4

      Here are top 10 stocks to focus on March 4 - MindTree, Tata Global Beverages, Eicher Motors, Bharti Airtel, Idea Cellular, Adani Ports, Adani Power, Sesa Sterlite, JSPL and Nitesh Estates. The research team at CNBC-TV18 is also tracking Tata Motors, Ranbaxy, L&T Finance Holdings and APL Apollo Tubes.

    • Prefer Sun Pharma, says Neeraj Deewan

      Prefer Sun Pharma, says Neeraj Deewan

      Neeraj Deewan of Quantum Securities prefers Sun Pharmaceutical Industries.

    • Buy Lupin 1600 Call, Ranbaxy 740 Call: VK Sharma

      Buy Lupin 1600 Call, Ranbaxy 740 Call: VK Sharma

      VK Sharma of HDFC Securities is of the view that one may buy Lupin 1600 Call and Ranbaxy Labs 740 Call.

    • Buy Ranbaxy, Apollo Tyres: Meghana Malkan

      Buy Ranbaxy, Apollo Tyres: Meghana Malkan

      Meghana V Malkan of malkansview.com is of the view that one may buy Ranbaxy Laboratories and Apollo Tyres.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347